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Introduction
Resistin is a 10 kDa protein composed of 94 amino acids. It was cloned in 
2001 and was shown to be a thiazolidinedione (TZD)-regulated cytokine 
expressed in adipose tissue.1,2,3 The effect of resistin on  insulin action 
has been extensively investigated in laboratory models.4 It was shown 
to be involved in hepatic glucose and lipid metabolism and appears to 
play a pivotal role in  hepatic insulin resistance (IR) induced by high-fat 
diet.5,6 Further studies on animal models suggested that resistin could 
represent a  link among obesity, insulin resistance, and diabetes.7 Data 
on the role of this adipokine in insulin sensitivity and obesity in human 
studies are controversial.8 Some studies indicated that high serum 
resistin levels are associated with increased obesity, visceral fat, insulin 
resistance, and type 2 diabetes, while others failed to show the same 
observations.9,10,11 
Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of 
disorders characterised by macrovesicular hepatic fat accumulation 
occurring in individuals without alcohol consumption. It is a complex 
metabolic condition in which both lifestyle and genetic factors play a 
pathogenic role.12,13 Moreover, NAFLD has been convincingly associated 
with the metabolic syndrome and insulin resistance.14 Insulin resistance, 
through inhibition of lipid oxidation and increased fatty acid and 
triglyceride synthesis, is believed to be a key factor in the development 
of fatty liver. Moreover, insulin resistance states, such as obesity and 
diabetes, are also characterised by altered production of adipokines 
(adiponectin, leptin, resistin, TNF, TGF, and plasminogen activator 
inhibitor-1). Because activation of inflammatory mechanisms was found 
in adipose tissue, it is possible that changes in the resistin concentration 
may be involved in the pathogenesis of NAFLD.15 Pagano et al reported 
that patients with NAFLD were characterised by higher serum resistin 
levels in association with the nonalcoholic steatohepatitis (NASH), 
whereas no correlation was found with insulin resistance.16 The aim 
of our study is to to determine circulating resistin levels obtained from 
patients with NAFLD and to correlate its levels with insulin resistance 
and hepatic histological features.
Materials and methods
Patients
A total of 30 consecutive patients with liver-biopsy-proven NAFLD 
from March 2007 to September 2007 at Cairo University Hospital (Kasr 
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El Aini Hospital) were enrolled in this prospective clinical trial. The 
30 persons recruited as a control group included healthy subjects who 
were matched with the studied patients in terms of age, sex and BMI. All 
study patients had had a liver biopsy either during laparoscopic or open 
cholecystectomy. All patients signed an informed consent document. 
The clinical trial protocol and the consent form were approved by the 
Human Investigational Board of Cairo University Hospital. The open 
liver biopsies were taken from the inferior border of the liver, while 
laparoscopic biopsies were taken from the epigastric port using scissors 
and diathermy for adequate haemostasis. 
All subjects underwent a detailed clinical and laboratory evaluation, 
including liver function tests, markers for hepatitis markers, and 
autoantibodies, in addition to upper abdominal ultrasonography. Alcohol 
consumption was absent in all subjects. Subjects with a previous or 
current history of acute or chronic viral hepatitis, malignant disease, 
acute infections, pituitary, adrenal, thyroid and pancreatic disease, 
or evidence for any other endocrine disorder, or prolonged use of 
corticosteroids or sex hormones were excluded. The controls had normal 
liver enzymes and no clinical, laboratory or imaging evidence of liver 
disease. Bright liver at ultrasound scanning was defined as an evident 
sonographic contrast between hepatic and renal parenchyma, vessel 
blurring, focal sparing, and narrowing of the lumen of the hepatic veins, 
according to international guidelines.17
Clinical and laboratory evaluation
Overnight (12-hour) fasting samples of serum were obtained from the 
study subjects and stored in aliquots at -70 ˚C until assayed. Clinical 
and laboratory data were collected on the date that the liver biopsy 
was performed. A complete medical history and physical examination 
was accomplished in all patients and controls. BMI was calculated 
using the following formula: BMI = weight (kg)/height (m)2. Laboratory 
evaluation included tests for liver enzymes, glucose, complete blood 
count, total cholesterol, triglycerides, viral serology for hepatitis B and 
C, and autoantibodies. C-peptide and insulin were measured by direct 
chemiluminescent technique, using an ADVIA centre immunoassay 
system, Bayer, Germany. The IR index was calculated on the basis of 
fasting values of plasma glucose and insulin according to the homeostasis 
model assessment for insulin sensitivity (HOMA) model formula: 
HOMA(IR) = fasting insulin (mIU/L) × fasting glucose (mmol/L)/22.5.
Resistin was measured using a commercially available sandwich ELISA 
kit (MBL International Corporation, Woburn, MA, USA) within the range 
of 16–20 000 pg/ml, according to the manufacturer’s instructions. The 
absorbance of each well was read using a microplate reader, stat fax 
2100 (Awareness Technology, Inc, Palm City, FL, USA). 
Liver histology
Liver biopsy specimens were at least 15 mm in length, had been 
fixed in neutral-buffered formalin, routinely processed and stained by 
haematoxylin and eosin, and Masson’s trichrome stain, for assessment 
of fibrosis. All biopsies had the appropriate number of portal tracts 
(a minimum of four portal tracts) to enable a confident evaluation of 
histological features and diagnosis.18 Liver biopsies were read by a 
single liver pathologist who was unaware of the patients’ clinical and 
laboratory data. All biopsies were interpreted, graded and staged by the 
Nonalcoholic Steatohepatitis Clinical Research Network scoring system 
(Nonalcoholic Steatohepatitis Activity Score – NAS), Kleiner et al, 2005, 
Tables I and II.
Degree of steatosis was assessed on a scale of 0–3: 1, mild (5%–33% 
of hepatocytes affected); 2, moderate (33%–66% of hepatocytes 
affected); and 3, severe (> 66% of hepatocytes affected). The grades 
of inflammation and stages of fibrosis were modified to two categories 
as follows: mild inflammation (Kleiner grade 1) and moderate-to-severe 
inflammation (Kleiner grades 2 and 3), mild fibrosis (stages 1 and 2), and 
advanced fibrosis (stages 3 and 4). 
Statistical analysis
Hepatic steatosis was assessed as categorical (absent or present) or a 
continuous variable from 0%–100%. Comparisons between the NAFLD 
group and controls were made using Student’s t test for continuous 
variables and the χ2 or Fisher’s exact probability test for categorical 
data. All values are presented, as mean ± SD. P < 0.05 was considered 
to be statistically significant. Multiple linear regression has been used in 
multivariate analysis of factors associated with resistin levels, including 
age, sex, degree of hepatic steatosis, BMI, C-peptide and IR.
Results
Comparison of patients and controls
Clinical and biochemical characteristics of the patients with NAFLD and 
controls are compared in Table III. Serum resistin levels were found to 
be significantly higher in patients with NAFLD as compared with the 
controls (P < 0.001), and higher in levels of insulin and HOMA than the 
controls. There was no significant difference in serum total cholesterol, 
Table I: Activity score








1 < 2 foci/200 x field
2 2–4 foci/200 x field
3 > 4 foci/200 x field
Ballooning 0 None
1 Few balloon cells
2 Many cells/prominent ballooning
Table II: Fibrosis staging
Stage Histologic criteria
1
Zone 3 perivenular perisinusoidal/pericellular fibrosis, 
focal or extensive 
· 1A – delicate perisinusoidal fibrosis 
· 1B – dense perisinusoidal fibrosis 
· 1C – portal-only fibrosis
2 As above with focal or extensive periportal fibrosis
3 Bridging fibrosis, focal or extensive
4 Cirrhosis
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triglyceride, C-peptide or glucose levels in patients with NAFLD when 
compared with the controls.
Gender difference in serum resistin
As expected, serum resistin levels were significantly higher in women 
than in men in the NAFLD group (P = 0.002).
Both men and women in the NAFLD group had higher mean serum 
resistin levels than did the men and women in the control group (all 
P < 0.001, Table IV).
Histological evaluation
Upon histological staging, steatosis was found to be mild in 17 patients 
and moderate to severe in 13; inflammation was mild in 16 and moderate 
to severe in 14; fibrosis was absent in 9, mild in 20, and advanced in 
one patient. As summarised in Table V, patients with moderate to severe 
steatosis had significantly higher levels of resistin than those with mild 
steatosis. Similarly, patients with moderate to severe steatosis were 
more insulin resistant, as indicated by higher values of HOMA(IR).
Relationship of serum resistin levels with BMI
To determine the relationship between obesity and resistin more clearly, 
the NAFLD patients were divided into two groups according to mean 
BMI (26.5) as a cut-off point. Thus, patients with a BMI of 26.5 were 
defined as being overweight. There were 12 patients with a BMI ≥ 26.5, 
and there were 18 patients with a BMI < 26.5. The serum resistin levels 
and HOMA(IR) values were significantly higher in the overweight group 
than in the normal weight group (P < 0.001 and P = 0.01, respectively) 
(Table VI).
Discussion
Our data shows that NAFLD patients have increased circulating resistin 
and that increased levels are correlated with insulin resistance, body 
mass index and histological severity of the disease. We found higher 
resistin in patients with histological diagnosis of NASH compared to pure 
fatty liver. Based on this finding, the present study is in agreement with 
the hypothesis that resistin may play a role in the progression of the 
natural history of NAFLD. In other studies, the relationship in humans 
between resistin and BMI and insulin resistance is under debate. 
Serum resistin was found by some authors to be increased in cases 
of obesity and to be positively correlated with BMI or body fat.19–23 Our 
hypothesis is partially supported by data reported by Bajaj et al 2004, 
who showed that serum resistin correlated with hepatic fat content and 
hepatic insulin resistance, but not with peripheral insulin resistance 
in type 2 diabetic patients.24–27 A major target organ of resistin is the 
liver, where resistin induces insulin resistance and increases glucose 
production. This concept was supported by experiments in rodents that 
clearly showed a major role of resistin in hepatic glucose metabolism 
and in the pathogenesis of diet-induced hepatic insulin resistance.28,29 
The findings of the present study show that resistin is involved in 
metabolic abnormalities that lead to steatosis in NAFLD patients. The 
serum resistin level was significantly higher in women. The difference 
is, therefore, in part, due to the higher percentage of body fat in women. 
In addition, our study showed that serum resistin levels were strongly 
correlated with BMI or fat mass, consistent with a number of previous 
studies.30,31,32 Also, the above results suggest a significant difference 
between normal-weight and overweight NAFLD patients with regard to 
serum resistin levels. 
One of the important results of the study was that higher serum resistin 
levels were detected in patients with moderate to severe steatosis, 
compared with mild steatosis. There are two most likely explanations 
for this finding. Firstly, resistin is related to IR. It has been suggested 
that resistin may contribute to hepatic steatosis by promoting IR and 
Table III: Clinical and laboratory data of patients with NAFLD and controls
NAFLD Control P-value
n 30 30
Gender (female/male) 15/15 16/14 0.8
Age (years) 41.96 ± 8.36 43.94 ± 8.35 0.375
BMI (kg/m2) 26.48 ± 3.11 23.98 ± 1.88 < 0.001
Total cholesterol (mg/dl) 159 ± 32.1 153 ± 25 0.446
Triglyceride (mg/dl) 137 ± 54 116 ± 34 0.075
C-peptide (nmol/L) 1.78 ± 0.29 1.8 ± 0.34 0.505
Glucose (mg/L) 98 ± 17 90 ± 12 0.072
Insulin (mU/L) 14.22 ± 2.66 8.64 ± 1.88 < 0.001
HOMA(IR) 3.46 ± 1.04 1.92 ± 0.45 < 0.001
< 0.001 2.72 ± 0.97 4.5 ± 1.52 Resistin (ng/ml)
Table IV: Resistin results according to gender
Male Female
NAFLD Control P NAFLD Control P
 n 15 14 15 16
Resistin
(ng/ml)
4.3 ± 1.42 2.3 ± 0.94 < 0.001 5.5 ± 1.57 3.2 ± 0.99 < 0.001
Table V: Resistin results in relation to degree of steatosis
Steatosis (n = 30)
Mild Moderate to severe P
n 17 13
Gender (female/male) 9/8 6/7 0.7
HOMA(IR) 2.98 ± 0.86 4.20 ± 0.83 0.001
Resistin (ng/ml) .72 ± 1.76 6.42 ± 1.64 0.004
Table VI: The results of BMI and resistin levels in NASH patients with normal 
weight and those that are overweight
Overweight Normal weight P
n 12 18
Female/male 8/4 9/9 0.5
HOMA(IR) 4.07 ± 1.05 3.13 ± 0.88 0.01
Resistin (ng/ml) 6.83 ± 1.46 4.52 ± 1.14 < 0.001
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by altering insulin signalling in hepatocytes, so as to promote increased 
intracellular levels of fatty acids.33 Moreover, at a later stage, resistin may 
cause hepatic steatosis to turn into steatohepatitis by amplifying selected 
pro-inflammatory responses.33 This explanation is based mainly on the 
effect of insulin on hepatic fat metabolism. In this study, an elevation of 
serum insulin level and HOMA (IR) was detected in NAFLD patients, by 
comparison with the controls, which supports the latter suggestion. Both 
IL-6 and TNFα may have a role in NAFLD patients, as many studies prove 
that their levels improve with lifestyle modification, together with the 
improvement of liver damage.34 Therefore it is possible that resistin may 
participate in the pathways underlying liver damage and the progression 
of pure fatty liver to NASH and fibrosis.35 Furthermore, we cannot rule 
out the possibility that increased resistin in NAFLD patients may come 
also from increased production in immune and inflammatory cells. As 
the hepatic stellate cells produce a variety of cytokines, it may be that 
elevated circulating resistin reflects increased resistin production by 
these cells inside the liver.36 This requires further study in order to be 
proved. The inconsistent link between serum resistin, obesity and insulin 
resistance may also be explained by genetic factors. It has been reported 
that a genetic polymorphism in the promoter region of the resistin gene 
may be an independent predictor of circulating resistin in humans.37,38,39 
Hence it is not possible to exclude that this gene polymorphism may be 
responsible for high resistin levels in NAFLD patients.
Conclusion 
Our study reported higher resistin levels in the serum of NAFLD patients, 
which were correlated to insulin resistance, adiposity and histological 
effect on the liver. The precise molecular mechanisms of these findings 
still need to be clarified. Further prospective studies are needed to 
prove the predictive value of the serum resistin levels for progression of 
NAFLD, change in the body fat, and change in insulin resistance.
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